Evommune, Inc.
NYSE:EVMNBiotechnology
-$0.17 today
- Market cap
- $284.49M
- Beta
- 0.10
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$2.26
Volume 0.60M
Average 0.38M
EVMN Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Evommune, Inc.NYSE: EVMN
Retained Earnings · Q1 FY2026 · quarter ended Mar 2026
Retained earnings remains negative
Q1 FY2026 retained earnings was -$242.76M, compared with -$166.78M a year earlier.
Context
- Retained earnings amounted to 75.3% of total assets at the end of Q1 FY2026, down 222.4 pp from a year earlier.
- Retained earnings grew in size in 2 of the last 2 fiscal years.
- FY2025 was the largest annual figure in the 3 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -45.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (221.09M) USD
- Year-over-year change
- -45.2%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (221.09M) | -45.2% |
| FY2024 | 2024-12-31 | (152.22M) | -81.4% |
| FY2023 | 2023-12-31 | (83.91M) | — |
Retained Earnings vs competitors
How EVMN compares with its peers on the latest reported figures
- EVMN's Mar 2026 retained earnings of -$242.76M is the 3rd highest of the 10 companies compared; the peer median is -$615.48M.
- Its year-over-year change of -45.6% is the lowest of 10, against a peer median of -13.9%.
- Retained earnings amounts to 75.3% of total assets for EVMN, versus a peer median of 199.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $583.25M | +26.4% | +10.5% | 26.7% | |
| Mar 2026 | -$173.89M | -45.4% | — | 59.2% | |
EVMNEvommune, Inc. | Mar 2026 | -$242.76M | -45.6% | — | 75.3% |
CLYMClimb Bio, Inc. | Mar 2026 | -$303.45M | -21.1% | — | 199.2% |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | -$354.07M | -32.6% | — | 334.2% |
| Mar 2026 | -$615.48M | -5.5% | — | 475.8% | |
| Sep 2026 | -$1.01B | -13.9% | — | 85.8% | |
| Mar 2026 | -$1.19B | -29.6% | — | 412.8% | |
FTREFortrea Holdings Inc. | Jun 2026 | -$1.42B | -6.4% | — | 52.3% |
| Mar 2026 | -$1.78B | -12.3% | — | 1355.9% | |
| Peer median (excluding EVMN) | -$615.48M | -13.9% | +10.5% | 199.2% | |
Competitors are the stored peer set for EVMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Evommune, Inc.
NYSE:EVMN
Intrinsic Alpha fair value
Locked
Current Price
$6.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.